Immunotoxicity of immunotherapeutic agents.
Johnson
A G
AG
Regal
J
J
D000119:Acetylmuramyl-Alanyl-Isoglutamine / Q000633:toxicity; D001379:Azathioprine / Q000633:toxicity; D003520:Cyclophosphamide / Q000633:toxicity; D003524:Cyclosporins / Q000633:toxicity; D005938:Glucocorticoids / Q000633:toxicity; D006046:Gold / Q000633:toxicity; D006801:Humans; D007109:Immunity / Q000187:drug effects; D007167:Immunotherapy / Q000009:adverse effects*; D007542:Inosine Pranobex / Q000633:toxicity; D007978:Levamisole / Q000633:toxicity; D008070:Lipopolysaccharides / Q000633:toxicity; D009369:Neoplasms / Q000188:drug therapy / Q000628:therapy; D010396:Penicillamine / Q000633:toxicity; D011131:Polyribonucleotides / Q000633:toxicity
D003524:Cyclosporins; D005938:Glucocorticoids; D008070:Lipopolysaccharides; D011131:Polyribonucleotides; D007978:Levamisole; D000119:Acetylmuramyl-Alanyl-Isoglutamine; D006046:Gold; D003520:Cyclophosphamide; D010396:Penicillamine; D001379:Azathioprine; D007542:Inosine Pranobex